Role of Calpastatin in mutant SOD1-mediated motor neuron disease

Calpastatin 在突变 SOD1 介导的运动神经元疾病中的作用

• 批准号: 7845533
• 负责人: MALA V RAO
• 金额: $ 19.75万
• 依托单位: NATHAN S. KLINE INSTITUTE FOR PSYCH RES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-05-15 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7845533
• 关键词: Age-Months; Amyotrophic Lateral Sclerosis; Animals; Axon; Biological Assay; Brain; Breeding; Calpain; Cell Death; Cessation of life; Clinical; Cysteine Protease; Cytoskeletal Proteins; Data; Disease; Disease Progression; Electron Microscopy; Family history of; Female; Figs - dietary; Gene Proteins; Genes; Glutamate Transporter; Goals; Human; Immunoblotting; Individual; Life; Limb structure; Longevity; MAP1 Microtubule-Associated Protein; Mediating; Modeling; Molecular; Monitor; Motor; Motor Neuron Disease; Motor Neurons; Mus; Muscular Atrophy; Mutant Strains Mice; Mutation; Neurofilament Proteins; Neurons; Onset of illness; Oxides; Paralysed; Patients; Peptide Hydrolases; Performance; Polymerase Chain Reaction; Protease Inhibitor; Proteins; Proteolysis; Role; Rotarod Performance Test; Signaling Molecule; Skeletal Muscle; Southern Blotting; Spectrin; Spinal Cord; Symptoms; Techniques; Testing; Time; Transgenic Mice; Transgenic Organisms; Ventral Roots; apoptosis inducing factor; base; calpain inhibitor; calpastatin; caspase-3; human male; human subject; immunocytochemistry; improved; inhibitor/antagonist; killings; motor neuron degeneration; mouse model; mutant; neurofilament; overexpression; prevent; protein degradation; public health relevance; retinal rods; sciatic nerve; skeletal muscle wasting; tau Proteins

DESCRIPTION (provided by applicant): Amyotrophic lateral sclerosis (ALS) is a devastating motor neuron disease and most of the patients die within 3-5 years after disease symptoms are seen. About 90% of the cases the cause of the disease is unknown (sporadic-ALS or S-ALS). About 20% of the cases of the patients that have a family history (F-ALS) have mutations in super oxide dismutase 1 gene (SOD1). Mutant genes from human-ALS patients have been used to construct transgenic mice that overexpress mutant human- SOD1 proteins. These mice develop clinical symptoms very similar to ALS patients such as loss of motor neurons, skeletal muscle atrophy associated with hind limb paralysis and ultimate death. Although, these mouse models have been around for more than a decade the cure is not available for ALS. Recent evidence suggests that neuronal protease calpain is abnormally activated and it may be responsible for degeneration of motor neurons in ALS. The best way to inactivate this protease is to inhibit with its own endogenous inhibitor calpastatin (CAST). We have developed a transgenic mouse line that expresses very high levels of CAST in motor neurons. We will breed CAST Tg mice with mouse model of ALS, hSOD1G93A mice to prevent motor neuron degeneration in ALS mice. Our preliminary data suggests that CAST overexpression in hSOD1G93A mice results in increased survival of motor axons and the double transgenic mice (hSOD1G93A/CAST) live 3.4 months longer than hSOD1G93A mice alone. Based on these observations, we propose that overexpression of CAST in mutant SOD1G93A mice will inhibit motor neuron degeneration and prolong the life span of the animals. The results obtained from our project will help to develop specific calpain inhibitor therapy for ALS. We will use mouse breeding techniques, Southern Blotting, polymerase chain reactions, immunoblotting, immunocytochemistry, electron microscopy and Rotarod tests to achieve our goals. PUBLIC HEALTH RELEVANCE: Amyotrophic lateral sclerosis (ALS) is a devastating motor neuron disease and patients die within 3-5 years after disease onset. We will test a protease inhibitor (Calpain-inhibitor, CAST) treatment in mouse model of ALS to prevent motor neuron disease. If we succeed with our approach, we would like to develop specific calpain inhibitor therapy for ALS.

肌萎缩侧索硬化症（ALS）是一种破坏性的运动神经元疾病，大多数患者在出现疾病症状后3-5年内死亡。大约90%的病例病因不明（散发性ALS或S-ALS）。在有家族史的F-ALS患者中，约有20%的患者存在超氧化物歧化酶1基因（SOD 1）突变。来自人ALS患者的突变基因已被用于构建过表达突变人SOD 1蛋白的转基因小鼠。这些小鼠发展出与ALS患者非常相似的临床症状，例如运动神经元丧失、与后肢瘫痪相关的骨骼肌萎缩和最终死亡。尽管这些小鼠模型已经存在了十多年，但ALS的治疗方法仍然存在。最近的证据表明，神经元蛋白酶钙蛋白酶被异常激活，它可能是负责ALS运动神经元的变性。抑制这种蛋白酶的最好方法是用其自身的内源性抑制剂钙蛋白酶抑制蛋白（CAST）进行抑制。我们已经开发了一种转基因小鼠系，在运动神经元中表达非常高水平的CAST。我们将CAST Tg小鼠与ALS小鼠模型hSOD 1G 93 A小鼠一起饲养，以预防ALS小鼠的运动神经元变性。我们的初步数据表明，CAST在hSOD 1G 93 A小鼠中的过表达导致运动轴突的存活增加，并且双转基因小鼠（hSOD 1G 93 A/CAST）比单独的hSOD 1G 93 A小鼠多活3.4个月。基于这些观察结果，我们提出在突变型SOD 1G 93 A小鼠中过表达CAST将抑制运动神经元变性并延长动物的寿命。本研究的结果将有助于开发针对ALS的特异性钙蛋白酶抑制剂治疗。我们将使用小鼠育种技术，Southern印迹，聚合酶链反应，免疫印迹，免疫细胞化学，电子显微镜和旋转棒测试，以实现我们的目标。公共卫生相关性：肌萎缩侧索硬化症（ALS）是一种破坏性的运动神经元疾病，患者在发病后3-5年内死亡。我们将在ALS小鼠模型中测试蛋白酶抑制剂（钙蛋白酶抑制剂，CAST）治疗以预防运动神经元疾病。如果我们的方法取得成功，我们希望开发针对ALS的特异性钙蛋白酶抑制剂疗法。